Last reviewed · How we verify
(Arm Closed) Dalteparin
Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.
Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. Used for Venous thromboembolism prophylaxis, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome.
At a glance
| Generic name | (Arm Closed) Dalteparin |
|---|---|
| Sponsor | University of Melbourne |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Antithrombin III (indirect); Factor Xa and Thrombin (downstream targets) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Dalteparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of activated clotting factors, particularly factor Xa and to a lesser extent thrombin. This prevents thrombus formation and propagation. It is administered subcutaneously and has predictable pharmacokinetics compared to unfractionated heparin.
Approved indications
- Venous thromboembolism prophylaxis
- Treatment of deep vein thrombosis and pulmonary embolism
- Acute coronary syndrome
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site reactions
- Elevated transaminases
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- (Arm Closed) Dalteparin CI brief — competitive landscape report
- (Arm Closed) Dalteparin updates RSS · CI watch RSS
- University of Melbourne portfolio CI